Cholesterol synthesis disruption combined with a molecule-targeted drug is a promising metabolic therapy for EGFR mutant non-small cell lung cancer

Youli Luo, Yunpeng Yang, Peijian Peng, Jianhua Zhan, Zhihui Wang, Zhiquan Zhu, Zhonghan Zhang, Lin Liu, Wenfeng Fang, Li Zhang